Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junye Wang

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
BMJ (Clinical Research Ed.)|April 20, 2022
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trialZhihao Lu, Junye Wang, Yongqian Shu, et al.
Molecular Cancer|January 11, 2019
Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencingYaxiong Zhang, Lianpeng Chang, Yunpeng Yang, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancerYaxiong Zhang, Lianpeng Chang, Yunpeng Yang, et al.
Nature Communications|February 15, 2022
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)Jianming Xu, Yi Li, Qingxia Fan, et al.
The Lancet. Oncology|June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 studyZhenggang Ren, Jianming Xu, Yuxian Bai, et al.
Eclinicalmedicine|May 27, 2024
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 studyZhihao Lu, Li Kong, Buhai Wang, et al.
Nature Medicine|June 1, 2026
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialZhi Peng, Tianshu Liu, Hua Wang, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
European Radiology|February 6, 2020
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trialZhigang Wei, Xia Yang, Xin Ye, et al.
Cancer Cell|March 4, 2022
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trialZi-Xian Wang, Chengxu Cui, Jun Yao, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
BMJ (Clinical Research Ed.)|April 20, 2022
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trialZhihao Lu, Junye Wang, Yongqian Shu, et al.
Molecular Cancer|January 11, 2019
Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencingYaxiong Zhang, Lianpeng Chang, Yunpeng Yang, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancerYaxiong Zhang, Lianpeng Chang, Yunpeng Yang, et al.
Nature Communications|February 15, 2022
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)Jianming Xu, Yi Li, Qingxia Fan, et al.
The Lancet. Oncology|June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 studyZhenggang Ren, Jianming Xu, Yuxian Bai, et al.
Eclinicalmedicine|May 27, 2024
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 studyZhihao Lu, Li Kong, Buhai Wang, et al.
Nature Medicine|June 1, 2026
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialZhi Peng, Tianshu Liu, Hua Wang, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
European Radiology|February 6, 2020
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trialZhigang Wei, Xia Yang, Xin Ye, et al.
Cancer Cell|March 4, 2022
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trialZi-Xian Wang, Chengxu Cui, Jun Yao, et al.
Pageof 10